Transcript
Recall please that we were discussing last time the fact that uh the immune system makes a a wide diversity of antibbody molecules. And by the way a synonym for an antibbody molecule is an imunoglobulin. Recall that we we used that word very briefly. Another word we used by the way was the word antigen. And an antigen is a functional term. That was pretty funny. Uh, an antigen is a functional term. An antigen is an agent that provokes an immune response. And the term antigen doesn't really refer to any specific chemical structure. Uh, it doesn't even it doesn't even have to be a protein. Antigen simply refers to some chemical entity that creates some response from the immune system.
We also use the word in passing epitope. And an epitope uh refers to a small region of for example a protein against which an antibbody has developed reactivity. And if you recall our discussion last time, a protein obviously of some size has multiple distinct epitopes which can each of which can be recognized by a distinct antibbody molecule. And for us, could we uh I'm sorry if I got all this political discussion started. Thank you. Um an epitope from the point of view of a protein is an oligopeptide. So a a stretch of amino acids of maybe uh 10 or 12 or 15 amino acids forms an epitope and therefore you can imagine there are multiple epitopes on the surface of a protein.
In fact, antibodies can sometimes recognize the internal parts of the protein because proteins can sometimes become undenatured or degraded. Indeed, as we will discuss shortly, proteins also become cleaved into oligopeptides. These olopeptides can come from any part of the protein to state the obvious and therefore there might be internal epitopes that exist in a protein that are not normally exposed by the native protein. Recall that we were dealing with the issue of how the immune system is able to create a wide diversity of antibodies imoglobulins which share in common a constant domain. Um and the constant domain is formed by these invariant regions of the light and the heavy chains.
Recall this is a heterotetimer in contrast to the variable domain up here which recognizes the antigen that initially provoked the production of this antibbody molecule. And the immune system may at any one point in time be making hundreds of thousands maybe even millions or tens of millions of distinct antibbody species that differ one from the other by the antigen recognition site here at this part of the antibbody molecule. And recall as well that since these are proteins, the antigen recogn recognizing pocket is itself an olopeptide which can bind in some complimentary fashion to whatever antigen initially provoked the um synthesis of uh this uh this antibbody molecule.
At the last at the end of last time we we discussed the fact that antibodies are made by B cells and the fact that in the disease of multiple myyoma one ends up with a monoclonal disease. That is to say, one of a vastly heterogeneous population of B cells begins to proliferate uncontrollably. And now all of its descendants make a single antibbody species. And that single antibbody species consists once again of a heavy and a light chain u whose identity is created by the antigen recognizing pocket that it happens to carry. And this begins to suggest a notion of clonal expansion. By that I mean the following.
Let's imagine a scenario where we start out with a naive immune system where we have a whole series of different B cells and this series goes here from 1 to 15 but in fact this could go from one up to a million and each of these anti uh antibbody producing B cells or each of these B cells has in principle the ability to respond to a different antigen. Let's just imagine that. And now what we can imagine is that a antigen such as for example polio virus comes into the body and it is recognized by two different uh clones of these B cells. And that recognition we can imagine acts as a mgenic signal a growth stimulatory signal for these two particular clones of B cells.
It almost acts as if it were a growth factor. But of course we're not talking about growth factors here. We're talking about antigens including antigens brought into the tissue by a foreign infectious agent and therefore the recognition of the antigen by the uh by these two uh B cells may thereafter provoke their clonal expansion. By that I mean to say that they will preferentially begin to proliferate. Whereas all the other B cells which are not in any way responsive to that antigen will just sit there like bumps on a log. And if there is therefore clonal expansion now there will be a much larger number of cells in the immune system that are capable of producing the antibbody that recognizes this provoking antigen.
Again recall that this number may go up to a million. This is just a great simplification. Now here we use the word plasma cells and in fact if one wants to get the the nomenclature very proper the plasma cells are the products of B cells which mature into the antibbody producing plasma cells. They're very close on the same uh lineage of cells. Um, and what that means in the end for us is that once there's an active immune response, there's been the preferential expansion of certain subpopuls of B cells and plasma cells and other ones of them which don't recognize these antigen just sit there and are under represented in the total population of cells.
Still, the fundamental question that we posed last time was the following. If it's the case, and it happens to be, that each of these B cells makes a an antibbody having a distinct reactivity, a distinct ability to react to one or another antigen. How do they make so many different kinds of antibbody molecules? How do they know how to do that? We argued that it's implausible that the amino acid sequences of each antibbody molecule are encoded in the germ line. Why? Well, if there are indeed a million or even a hundred million distinct antibodies that can be made by the immune system, clearly there can't be a hundred million genes, each of which is dedicated to the production of a distinct um antibbody molecule.
And the solution to this puzzle was f first worked out by Susumu Tonagawa already more than 20 years ago who happens to be in our biology department. And what he uh discovered was the following that the way that the antibbody uh producing genes are organized is really quite extraordinary and unusual. Here's the heavy chain uh gene. And keep in mind that there's a heavy and a light chain gene. The heavy and the light chain genes are in different chromosomes. And therefore the genes that are responsible for encoding these two proteins the heavy and the light chain they are on different chromosomes uh and encoded by different genes.
Okay. So what Tanagawa discovered was the following that the variable region of an antibbody molecule which is at its end terminus is encoded by small segments of DNA that are carried in one very large genetic locus an imunoglobulin locus. And what happens in humans is the following. There are uh there are in humans rather than mice. This number should be 100 in humans. There are 100 distinct V segments that are encoded in the um in this antibbody locus. Each one has is of roughly the same size and they're located in a large tandem array. Similarly, there are in humans 30 of these D segments. The numbers change here if one goes from mouse to human, but that's irrelevant.
And there are six of the J segments. And much of the antigen recognizing capacity much of the variable region is encoded in in the the green and the blue region of the gene. And the encoding happens as follows. There is in a combinatorial fashion the random fusion of V, D and J segments. There are specific highly specialized enzyme that will choose one specific V segment, one specific D segment and one specific J segment ostensibly on a stochastic basis, a totally random basis and fuse them together. And if that happens and we uh and and the intervening DNA sequences are discarded then right away we can see that through the combinatorial mathematics that results from this there is the possibility for having 100 * 30 which is 3,000 * 6 which is already 180,000 distinct combinations in encoding the reading frame of this particular um antibbody molecule here I've just said V23 I S D7 J2 but again let's imagine uh which is approximately the case that each of these combinations can be fused with roughly equal probability what happens subsequently then is that this variable region sequence which has been formed by fusion is then um the transcript that comes from that is spliced to the constant region which is toward the C terminus.
So here when we talk about the the VD and J segments, we're talking about the segments that are encoding this portion. Here's it this portion of the antibbody molecule. Keep in mind from here on down, we're talking about constant region uh segments which are not affected by these per um combinatorial fusions. And in the uh overhead I just showed you, I was just talking about how the heavy chain gene is rearranged. And what that results as a consequence is the following. This is just another version of what I just showed you before where the V D and J segments become uh fused uh randomly to one another creating a VD J fusion thing which then by splicing is fused to the constant region which here is called uh C sub mu for reasons of why it's called submu I'll mention in a moment.
And this is the actual messenger RNA which then goes into the cytoplasm. And what we can now imagine is the following that when the immune system first begins, it randomly fuses whole series of VD and J segments together in all kinds of combinations. The same happens in both the heavy chain and the light chain. Although the light chain is slightly simpler, but that's irrelevant for us conceptually. And then we end up having hundreds of millions of distinct B cells each of which has a different combination of V uh of heavy and light chains because keep in mind the light chain genes are also being rearranged combinatorally.
They're also being fused and therefore we are we can have 180,000 combin 180,000 distinct heavy chains and um I forget the exact number for the number of light chains. it's a bit less. But we can multiply those two combinations by one another because keep in mind that the the gene encoding the um the heavy chain here and its variable region and the gene encoding the light chain and its variable region are are organized on separate chromosomes and they're fused together. These segments are fused together randomly. So the total number of antibbody molecules we can make is 180,000 distinct kinds of these and I've just slipped up on knowing the total number of these that can be made although we could figure it out shortly if it were really important but once again the number is in the many thousands and therefore overall the total number of distinct antibbody molecules one can make on the basis of this is this did I get the math right 60 by 30 18,000 it was 18,000 So there's 18,000 distinct of these that can can be made and the number of these I think is closer to 10,000 I forget.
But multiply there's a let's call it 10,000 for a moment. That's not the right number. There's 10,000 different ones of these and 18,000 of these that can be made. multiply them together and you get the total number of combinations of antibiotic molecules that can made because it is the case that the antigen recognition site here is created cooperatively collaboratively by the heavy and light chain. you you had a question. So the the uh the gene is rearranged and when the arrange rearrangement occurs one V gene one V segment is fused to one D segment is fused to one J segment and and all of the extraneous segments that are between them have been deleted from the chromosome.
So this leads me to a second point I want to make and that is that here we are dealing with a process of somatic mutation. We talked about last time or the time before last the fact that somatic mutation is generally a process that can lead to cancer i.e the mutation of germline genes that are in one way or another corrupted by random mutational processes. But here I'm talking about a somatic mutational process which is highly directed and highly organized and focused on creating a series of rearranged genes that can then serve as the the template for the um production of uh of of a antibbody molecule.
So here let's just look at this again here I'll tell you there are many V genes there are many D genes and there are many uh J genes and this is the embryionic DNA after large segments of the imunoglobin locus are deleted and the surviving V then the surviving VD and J segments become fused in the DNA directly to one another and when that happens the resulting uh B cell DNA can be transcribed and vup splicing create an mRNA where the region in between the J's chain and the constant region chain called here C is further deleted. So each messenger RNA has one V, one D and one JC segment together with a constant region segment.
There are yet other processes that further diversify how many different variable regions can be encoded. One of them is the following. It turns out that the process by which the V and D and the D and J genes are fused together, those segments are fused together is a bit sloppy and therefore sometimes the fusion will occur creating a a a sequence of of nucleotides that's that has a a nonsense code on in. Sometimes it will create a coherent reading frame that creates yet another kind of amino acid sequence there. And therefore this is not a highly ordered uh process in the sense that the the um micro architecture of the points where the V and the D and the D and the J are fused is is a little bit chaotic.
So that creates even further randomization of the nucleotide sequence. And then finally once this gene has been uh created there is a process which is called hypermutation where through mechanisms which are not well understood the nucleotide sequence of this region is actually uh uh further changed. It's mutated by certain enzymes. For example, there's an enzyme called cytoine diaminise which takes off the amine group off of the cytoines in that region and thereby effectively converts the C's in that coding region more into having a T coding capacity. This happens somatically and here once again I'm talking about a further dimension of diversification.
What are the dimensions of diversification? First of all the V and the J chains rearrange um independently randomly and stochastically. Secondly the joining of the segments is is a bit sloppy. And thirdly there is somatic hypermutation. There's an enzyme like this which is actually an actively mutagenic enzyme which fiddles around with some of the C's in this portion of the gene thereby further diversifying the uh coding um ability of the imunoglobulin um gene that's encoded by the cell and what this means is the following that if we imagine this scheme here where each of these B cells recognizes a different um uh antigen Initially there may be uh a 100 million distinct B cell clones that are created each the consequence of a different random mutation that happens early in the development of the immune system.
Thereafter there are certain selective processes that are at play. One important selective process is the elimination of B cells that have failed to make nicely rearranged antibbody molecules. What do I mean by that? I told you how sloppy the VDJ joining is and therefore many of these joinings could create reading frames that are incoherent with stop codons in the middle and therefore those cells which happen to have created antibbody molecules which are highly mutant and clearly structurally defective are eliminated. So, one prerequisite for the survival of these B cells early in the uh development of the immune system is that they've learned how to make functional V heavy and light chains.
If they don't, they're right away wiped out. They're they're eliminated. Here's another very important um uh prerequisite for survival. That these B cells don't make antibodies that react with antigens that are native to the body's own tissues. What do I mean by that? Well, one of the wonders of the immune system is the following. That it can recognize foreign antigens that are brought into the body from the outside, including, for example, the epitopes on the surface of a polio virus particle. It can recognize many different viruses, surface antigens present on the surface of bacteria and fungi and all kinds of other infectious agents.
But importantly, the immune system also sees hundreds of millions of different epitopes of the proteins that are present endogenously, native proteins in our tissues. A priori, the native proteins, the self, what's called our own self proteins are perfectly qualified to function as antigens. And yet the immune system rarely develops strong reactivity against them. That thus the immune system has the ability to recognize self versus non-self. What do I mean by self versus non-self? Self are the body's own native proteins which are in principle conceivably antigenic. Non-self are foreign invaders that are that bring strange epitopes into the cell.
And what happens is that the is that B cells which make antibodies that recognize native proteins in our tissues are if things are working well rapidly eliminated early in the development of the immune self in the of the immune system. What happens if that elimination fails to occur properly? If it fails to occur, one has the process of autoimmune disease. And there are multiple autoimmune diseases. Um, type 1 diabetes, early onset diabetes, happens when the immune system recognizes antigens that are present in the eyelet cells in the pancreas that make insulin. Rheumatoid arthritis which afflicts a large portion of the elderly happens when um the immune system recognizes antigens that are present normally in the cartilage in our joints.
Lupus happens when lupus is a dis autoimmune called lupus which is often fatal. Happens when the immune system uh recognizes proteins in many different tissues. And once again in all of these cases there is a breakdown of the mechanisms governing immune tolerance. And what do I mean by tolerance? I mean the mechanisms whereby the immune system tolerates native antigens but is conversely intolerant of foreign antigens. The word intolerant is not used in immunology but I'm just using it for the sake of explanation here. So immune tolerance is a very important area of current imunological research.
We don't really understand why we don't have much more autoimmune disease than we do. And by the way, I've only listed two or three of the most common kinds of autoimmune diseases that happen when the mechanisms that normally guarantee immune tolerance fail. And therefore, these B cells that survive are ones that make functional antibodies. And those um that do not whose antibodies do not recognize self antigens, they're permitted to survive. And once again, we imagine that those that happen to make uh antibodies that recognize particular foreign antigens undergo or enjoy clonal expansion. During the development of the immune response, there is a further diversification of the antigen recognizing domain of the protein by hypermutation.
And therefore, descendants of these initially developed cells which have begun to expand because they make an antibbody may develop antibbody molecules that are even more able to bind avidly to the antigen. It could be that initially these um antibodies producing molecules u these antibbody producing cells make antibbody molecules that bind nicely to the antigen but not really avidly. Avidly means really tightly and that's enough to get their clonal expansion going. But during the process of the um of uh clonal expansion this hypermutation creates further varants of these cells further mutates their antibbody producing genes so that the some of the descendants of these cells will produce antibbody molecules that bind even more tightly and specifically to the provoking antigen.
And when that happens the quality of the antibodies is improved progressively. Now clearly the somatic hypermutation once again c it's a random hypermutation and those clones of cells in which the hypermutation created less effective antibodies will not have their proliferation stimulated. Those clones of cells whose antibodies make more and more tightly binding antibodies will preferentially have their proliferation stimulated. and as a consequence they will now be the ones that are favored to produce the to yield the plasma cells that produce large amounts of antibbody molecules. So we have now this very unusual and very interesting way by which um B cells and plasma cells are able to create a wide diversity of antibbody molecules.
Now one of the interesting things actually is the fact that this constant region contains one of a variety of distinct constant regions. Initially when one produces the first immune response the first immune response as we said before produces a constant region which is called C subm and I have the right I overhead this morning. Ah, here it is. Here's the way the genes are actually rearranged. Here's the rearrange V, D, and J. And here's the splice to the constant region. And downstream are a whole series of constant region segments. What's the first one? C subm. I told you about that before. Thereafter C subdelta, C subgamma 3, gamma 1, gamma 2, gamma 8, and so forth.
each of and therefore the initial event can create an IG mu an IGM antibbody molecule the mu region creates an IGM later as the immune response develops further this mu segment may become deleted and now the splice may occur to a delta or a gamma chain and therefore if you uh If you if the intervening constant region is changed, you might get what's called an IGG. An IGG is an imunoglobulin which is produced when this antigen recognizing region becomes uh spliced down to here or here by virtue of the deletion of these intervening constant region segments. What's the purpose of what's called of class switching?
because these are different classes of antibodies because they have different functions. Note importantly that when this class switching occurs, it has no effect on the antigen recognizing site of the antibbody molecule. Rather, it affects the constant region of the antibbody molecule. Well, how does that work? The initially made antibbody molecule I told you is IGM. And in fact, if you look at the structure of IgM, it looks like this. Here's, let's say, a B cell. And the IgM molecule is actually not secreted into the extracellular space like a soluble antibody molecule. Here's what IgM looks like drawn very uh schematically.
IgM has our standard antigen recognizing site, but IgM is embedded in the plasma membrane of the B cell exactly the way that a growth factor is growth factor receptor is embedded in the plasma membrane of a B cell. But keep in mind that I just said that this um IGM molecule has an antigen recognizing domain up here which is exactly the way we described it before. So the antigen recognition is not affected by whether we have an IGM molecule here. only the location of the antibbody molecule and as I'll show shortly the function of this antibbody molecule is affected by this IGM where does it later on descendants of this B cell will mature into those that secrete IGG molecules into the into the uh into the plasma.
So here's a maturation that's going on. But look here once again the antigen recognizing domains of this IGG are unaffected by this conversion. Here the constant region is tethering the antibbody molecule to the plasma membrane. Here's the antigen recognizing sites. After this maturation occurs, these secreted IGG molecules which go into the solution have identical antigen recognizing sites, but now they're soluble proteins. Well, you say, why does the immune system do that? And it goes back to an overhead I showed you just moments ago um in which there was a puzzle implicitly created by what I uh by the uh the image on on the overhead.
And here it is. Let's look at this for a moment. What detail is now explained by this um uh by the on on in this scheme? What detail is now explained? I told you that B cells can be stimulated by certain antigens. Let's imagine that each of these B cells made only secreted antibbody. Okay, instead of making cell surface antibbody because the cell surface antibbody which is being made in this scheme is actually the IGM molecules. Let's say this B cell over here is making an antigen. I'll just draw it as a there's the antigen is making an antibbody against this antigen and it's secretreting antibbody against this and I just argue that the B cell that makes good antibbody is favored.
It has its proliferation stimulated. Right? That's what we talked about. But if this B cell sends all of its antibbody into the plasma, how is it going to know that it's making a good antibbody? It can't because all of the antigen recognition is happening by the secreted antibbody. So what happens with the IgM molecules? The first antibbody molecule that's produced is IgM and it stays tethered to the plasma membrane of the B cell. It's a transmembrane protein and it functions much like a growth factor receptor. That is to say, when the antigen binds out here, there are signals that are radiated into the cell that induce the proliferation of this cell.
And now these cells that produce the antigen antigen recognizing IGM molecules on their surface can now have their proliferation stimulated. That solves the puzzle here which is created by this scheme. If all these B cells just made secreted antibbody like this then there would be no way to encourage their proliferation because there would be no way of telling this B cell you're doing a good thing. Keep making more of these antibbody molecules. Here the antigen recognizing capability is embedded in the plasma membrane and when an antigen binds this the IgM molecule is organized so that now growth stimulatory signals are sent into the cell which cause this cell to begin to proliferate producing more IGM containing cells which are further stimulated to proliferate and ultimately after this has gone on for a while there is a class switching which deletes the IGM region of the gene the heavy uh uh chain region and causes a conversion to IGG.
Again, the conversion from here to here doesn't change the antigen recognizing capability of these two antibodies. It just makes a cell surface transmembrane protein or a secreted protein. You made it sound like the the uh the VDJ choice is part of mRNA processing. No, the VD choice happens in the nucleus. It's a fusion of different DNA segments. And when it's transcribed, that fused VDJ segment is now spliced to a constant region segment. So the choice of VDJ actually DNA. The choice of VDJ is a fusion of DNA segments. It happens in chromosomeal DNA. It results in the deletion of all the segments that aren't used.
So that's all that's left in the imoglobulin locus of a B cell is a a DNA segment encoding V fused to a DNA segment encoding D fused to a DNA segment encoding J. So now you have a new somatically mutated imoglobulin gene less there be any residual confusion about that. So you see you see the elegance of this class switching thing. Now there's yet other constant region segments that are used for other purposes. For example, um when you have allergies, there's a uh activation of the IG E antibodies. Um when you have um uh secreted uh antibbody production in the colon, it's IgA is used more for that.
So different ones of these constant regions are used for different imunological applications. The IgM molecule, as I've said, is used here just as a way of telling the B cell that it's done well by making the right kind of antigen recognizing site. The real business of creating antibodies is the soluble antibbody production, the imunoglobulins or the gamoglobulins because the vast majority of antibodies floating around the blood plasma are in fact IGGs. The IGMs are as implied by this actually just largely tethered to the surface of cells. So this really is an extraordinary ele elegant way of creating essentially hundreds of millions of different antigen recognizing domains each uh created collaboratively between a heavy and a light chain.
And once these antigen recognizing domains are created through changes in DNA structure then they can be used for different imunological applications driving bell proliferation secretreting soluble antibodies that are used to neutralize virus particles in the blood or uh if they're hyperactive to create allergic reactions or um to create uh immunity in in certain regions of the gut and so forth. So this class switching doesn't change the antigen recognizing capability. It just changes the utilization of um how already developed VDJ segments and their antigen recognizing capability are exploited by cells of the immune system.
Now, one thing that's not really clear by all this is how how all this develops at the cellular level because what I've talked about until now is called hummeral immunity. Well, we talk about somebody having a good sense of humor. But the actual original meaning of the word humor in Latin was fluids that were fluxing through your body and were responsible for your different mood states. So if you had were depressed or there just was a national election, there would be black fluids, black humors coursing through your blood. And if you were in a good mood, there were other humors coursing through your blood blood.
And that leads through this etmology to the term of hummeral immunity which is to say the soluble immunity i.e the production of soluble antibbody molecules. But I will tell you that there's a second arm of the immune system which is equally important and that's called cellular immunity. And to make a long story short, and we'll elaborate on it uh uh on on Monday uh briefly, cellular immunity is largely created when you have a a kind of immune cell. it's called a T- cell rather than the B cells we've been talking about until now which is able and this cellular immunity is among other things cytotoxic and it can recognize a second cell over here's a second cell this is its target cell because the second target cell is displaying on its surface certain antigens.
So antigens are being displayed on the surface of the uh target cell. I've indicated them here as just little blue strokes. And the T-C cell is able to recognize these antigens on the surface of this cell here and is able to kill this cell through a series of interesting mechanisms. This doesn't involve the intervention of soluble antibbody molecules. Here we're talking about one cell recognizing another and it turns out to be very important for antiviral defenses. I've told you one way by which antiviral defenses are achieved. Soluble antibbody molecules are secreted into the blood plasma like IGGs.
They recognize an epitope on the surface of a virus particle. They glom onto that epitope on the surface of the virus particle and they neutralize the virus particle and that's very important. We started out in our discussion of polio virus talking about that. But this also turns out to be very important. Why is it important? For the following reason when this cell let's say this cell is infected by polio virus on the inside. It turns out interestingly enough that the cell has a way which we'll discuss of processing polio virus polyeptides viral polyeptides and displaying them on the cell surface.
In other words, the cell can chew up some polio proteins, put them to the outside and tell the outside world, these are the kinds of proteins that are being made right now inside of me. You, the immune system, can't really look through the plasma membrane. So I'm going to tell you this is what's going on inside of me. There are polio virus proteins being made as we speak on the outside of the cell. The these are displayed even though polio replication is occurring exclusively inside the cell. A cytotoxic tea cell here may recognize these antigens on the surface of the polio virus infected cell and proceed to kill the cell.
Why is it why is that interesting or important? Because the cytotoxic cell will kill the virus infected cell while the virus infection is still in full swing. And therefore by killing the virus infected cell, it will abort the entire viral replication cycle because the virus won't have enough time to replicate and proliferate inside the infected cell before it happens. It's it's preemptively killed by the cytotoxic tea cell. And in fact, this way of eliminating viral infections from our body is as important and often more important than the neutralization of soluble virus particles in our plasma.
And all that gets now to uh to have us focus increasingly on the mechanisms by which antigens are recognized and processed so that the immune system can can begin to um respond to them. So I want to get into that now into the aspects in well in which we look at the cellular arms of the immune system. The most important thing initially in the immune response is that let's say a polio virus particle is recognized and digested by certain fagocitic cells of the immune system. What's a fagocitic cell? A cell that is able to gobble up other things. So a well-known fagocitic cell is a macrofase. And there you can see the term fagosite.
Macrofase. Fagos means to chew up or is a swallow. So macrofase might see a particle like this surround that particle and then internalize that particle and digest it. Let's say a polio virus particle. polio macrofase can envelop a polio virus particle and internalize it. It can do the same thing with a bacterium. Here we'll use as an abbreviation for macrofase this. So that's macrofage. There are yet other even more important fagocitic cells of the immune system that are called dendritic cells. Now these cells gobble up whatever happens to be around them. They don't care. They are promiscuous um sewer uh what do we call gutter trollers they whatever happens to be around they will gobble up whatever happens to be around they'll put it inside of them and now they do something really interesting the dendertitic cells the macrofasages the fagocitic cells they don't digest the the endo the internalized particles down to amino acids They digest the virus particle down to oligopeptides usually of 10 12 14 amino acids long.
Very important. So they don't make amino acids, they make olopeptides. Why are they doing this digestion? Because these cells are exhibitionists and they want to show the rest of the world what they've just swallowed up. It's really important to them. Go figure. So what do they do? They take these oligopeptides that they've just internalized and they put them on the cell surface via molecules which are called MHC class 2. MHC class 2 is the name of these molecules and these are cell surface receptors and these MHTC class 2 molecules have on have included in them this olop an olopeptide that has just been produced by the proteolytic cleavage of an internalized infectious agent let's say and so the macrofase has many of these MHC class two molecules on its surface and it displays to the outside world what it has just captured in in terms of these olopeptides.
And these olopeptides are by the way roughly the size of an epitope. Therefore, this macrofage is just so excited. It's like a little kid who's just found something is so excited to show the world what it's just found and gobbled up and processed. And over here is a class of cells which are called T-helper cells. And the T-helper cells are interesting in their own right. The T-H helpper cells have evolved through a mechanism that is similar to and parallel to the evolution of the B cells. As a consequence, there are many different kinds of T- helpper cells. each one. So, TH1, TH2, TH3, each of which displays on its surface a T-C cell receptor.
What kind of T- cell receptor does it display? A T- cell receptor that has gone through exactly the same kind of hoops that the antibbody genes have gone through. that is each TE-C cell expresses on its surface an antigen recognizing receptor just like the IGM molecule except it's made by T- cells and it's created by these stochastic processes of fusing DNA segments. So each of these TE-C cells and again there are millions of them has a different T- cell receptor with a different antigen recognizing capability. And here's what happens in the immune system. Let's imagine, as I say every year, that we're that um we're in a Middle Eastern bazaar.
And the Middle Eastern bazaar, here's all the stops, the shops on the sides on on the sides of this long bazaar. It's sometimes called a shook or a suk. And here we're going to have a macrofase or dendertic cell moving through the bizaar. Hanging out in front of the stores are a whole bunch of T-helper cells. Business is slow. So all these T-helper cells are just hanging out in front and is as is not the custom in this region. Let's pretend all the T-H helpper cells are girls just for the heck of it. Doesn't make any difference. And each of these T-helper cells is displaying its own TE-C cell receptor which has arisen through stochastic mechanisms and which recognizes a different oligopeptide.
And here we have now the macrofase coming through like a vendor, a street vendor saying, "Look girls, look at the epitope I've just gobbled up and produced. Isn't it great?" And it's using its MHC class 2 molecules to present. It's like hands presenting the epitopes. It's fgging them like a street vendor. And it walks down through this bazaar. And each of the the uh the tea helper cells. They're sitting there. They're congregating along the sides of the road. And they most of them say, "Look at this drip. Look at the garbage he's selling us today. I am totally uninterested. He was here last week with some other junk too.
Let's hope he disappears quickly. And meanwhile, the macrofase or the dendritic cell is very anxiously trying to find someone who has even the slightest bit of affection or respect for him. And this goes on for a long time. And finally, finally the macrofase finds a T-helper cell over here. So, here's the T-H helpper cell. And it turns out that by coincidence, the T-H helpper cell has on her surface a T-C cell receptor. T-C cell receptor that recognizes the epitope that the macrofase is pedalling. So, here's the macrofase. macrofase has on its surface this oligopeptide held by the MHC class two hands.
So here's the peptide and this T-C cell receptor which I'll abbreviate TCR recognizes binds strongly to the epitope that's being flogged by the um um by the macrofase. And this is I will tell you honestly love at first sight. She says, "Oh, I can't believe it. You're selling an epitope that I just happen to love. This is very exciting." And all the other tea helper cells say, "Oh my god, what does she see in him?" And she gets all excited because there's a direct complimentarity. In fact, to tell the truth, the T- cell receptor recognizes not only the epitope, but also the surrounding amino acids in the fingers of the MHC class 2 molecule.
It's this constellation of things that's recognized by the T- cell receptor and gets this T- cell receptor really excited. And what does she do? Well, we can't talk about everything because this is polite company, but most important for what she does is she begins to proliferate like mad. Well, you know, cells have a limited repertoire of behavioral routines. So, next time we're going to figure out how this leads to an immune response. So, we're going to be on intention all weekend.